{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positive+Control&page=3",
    "query": {
      "intervention": "Positive Control",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 1719,
    "total_pages": 172,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positive+Control&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positive+Control&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T13:17:55.826Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04849052",
      "title": "Text Messaging to Increase Activity in Midlife",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Middle Aged"
      ],
      "interventions": [
        {
          "name": "MASTERY",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Attentional Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "45 Years to 64 Years"
      },
      "enrollment_count": 116,
      "start_date": "2021-09-16",
      "completion_date": "2024-09-16",
      "has_results": true,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-11-02T13:17:55.826Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04849052"
    },
    {
      "nct_id": "NCT00104299",
      "title": "Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Vasculitis",
        "Wegener's Granulomatosis",
        "Microscopic Polyangiitis"
      ],
      "interventions": [
        {
          "name": "Rituximab plus cyclophosphamide placebo (rituximab group)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide plus rituximab placebo (control group)",
          "type": "DRUG"
        },
        {
          "name": "Azathioprine",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone (or other glucocorticoid)",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 197,
      "start_date": "2005-01",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-11-02T13:17:55.826Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104299"
    },
    {
      "nct_id": "NCT01999114",
      "title": "The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "ECG Effects"
      ],
      "interventions": [
        {
          "name": "Buprenorphine transdermal patch",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebos (for TDS and for naltrexone and for moxifloxacin)",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Purdue Pharma LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 328,
      "start_date": "2012-03",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2018-11-05",
      "last_synced_at": "2026-11-02T13:17:55.826Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01999114"
    },
    {
      "nct_id": "NCT04213274",
      "title": "Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schnitzler Syndrome",
        "Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)"
      ],
      "interventions": [
        {
          "name": "80 mg RPH-104",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "R-Pharm Overseas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-05",
      "completion_date": "2024-01",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-11-02T13:17:55.826Z",
      "location_count": 4,
      "location_summary": "Denver, Colorado • Rochester, Minnesota • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04213274"
    },
    {
      "nct_id": "NCT01068613",
      "title": "Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "QAX028",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2010-01",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-11-02T13:17:55.826Z",
      "location_count": 4,
      "location_summary": "Anaheim, California • Normal, Illinois • Spartanburg, South Carolina + 1 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01068613"
    },
    {
      "nct_id": "NCT00975650",
      "title": "Efficacy and Tolerability of an Intra-Nasal Testosterone Product",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Nasobol®",
          "type": "DRUG"
        },
        {
          "name": "Androderm® (Positive Control)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acerus Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "18 Years to 80 Years · Male only"
      },
      "enrollment_count": 57,
      "start_date": "2009-08",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2018-08-13",
      "last_synced_at": "2026-11-02T13:17:55.826Z",
      "location_count": 6,
      "location_summary": "Tucson, Arizona • Burbank, California • Miami Gardens, Florida + 3 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Miami Gardens",
          "state": "Florida"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00975650"
    },
    {
      "nct_id": "NCT06207318",
      "title": "Acceptance and Commitment Therapy for Patients Undergoing Coronary Artery Bypass Graft Surgery",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Vascularization"
      ],
      "interventions": [
        {
          "name": "Acceptance and commitment therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2024-02-12",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-08",
      "last_synced_at": "2026-11-02T13:17:55.826Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06207318"
    },
    {
      "nct_id": "NCT02324179",
      "title": "Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV Infected Children and Healthy Controls",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV",
        "Endothelial Dysfunction"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "8 Years to 30 Years"
      },
      "enrollment_count": 76,
      "start_date": "2014-08",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-03-09",
      "last_synced_at": "2026-11-02T13:17:55.826Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02324179"
    },
    {
      "nct_id": "NCT00412750",
      "title": "Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Telbivudine (LdT)",
          "type": "DRUG"
        },
        {
          "name": "peginterferon alpha-2a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 159,
      "start_date": "2006-12",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2011-07-13",
      "last_synced_at": "2026-11-02T13:17:55.826Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00412750"
    },
    {
      "nct_id": "NCT04899024",
      "title": "PrEP Affect Regulation Treatment Innovation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Medication Adherence",
        "HIV Prevention",
        "Stimulant Use"
      ],
      "interventions": [
        {
          "name": "PARTI",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Attention-Control",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Contingency Management for PrEP Adherence",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Florida International University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 239,
      "start_date": "2022-01-31",
      "completion_date": "2026-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-11-02T13:17:55.826Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Miami, Florida",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04899024"
    }
  ]
}